Tejara Capital LTD Arcutis Biotherapeutics, Inc. Transaction History

Tejara Capital LTD

$153 Billion
Q4 2024

A detailed history of Tejara Capital LTD transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Tejara Capital LTD holds 886,838 shares of ARQT stock, worth $11.5 Million. This represents 8.09% of its overall portfolio holdings.

Number of Shares

886,838

Previous 1,165,309 23.9%

Holding current value

$11.5 Million

Previous $10.8 Billion 13.99%

% of portfolio

8.09%

Previous 5.16%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 10, 2025	SELL	$8.31 - $14.99 $2.31 Million - $4.17 Million	-278,471 Reduced 23.9%	886,838 $12.4 Billion
Q3 2024 Nov 13, 2024	SELL	$8.32 - $11.0 $1.48 Million - $1.96 Million	-178,300 Reduced 13.27%	1,165,309 $10.8 Billion
Q2 2024 Aug 13, 2024	BUY	$7.24 - $12.53 $2.92 Million - $5.05 Million	403,122 Added 42.86%	1,343,609 $12.5 Billion
Q1 2024 May 14, 2024	SELL	$3.25 - $11.77 $558,122 - $2.02 Million	-171,730 Reduced 15.44%	940,487 $9.32 Billion
Q4 2023 Feb 12, 2024	BUY	$1.84 - $4.82 $1.48 Million - $3.87 Million	803,038 Added 259.73%	1,112,217 $3.59 Billion
Q3 2023 Nov 13, 2023	BUY	$5.31 - $10.98 $769,950 - $1.59 Million	145,000 Added 88.32%	309,179 $1.64 Billion
Q2 2023 Aug 11, 2023	BUY	$7.51 - $15.0 $497,004 - $992,685	66,179 Added 67.53%	164,179 $1.56 Billion
Q1 2023 May 12, 2023	BUY	$10.23 - $17.14 $409,200 - $685,600	40,000 Added 68.97%	98,000 $1.08 Billion
Q4 2022 Feb 13, 2023	BUY	$13.96 - $20.4 $809,680 - $1.18 Million	58,000 New	58,000 $858 Million

Others Institutions Holding ARQT

# of Institutions

218

Shares Held

129M

Call Options Held

2.02M

Put Options Held

202K

View Full List

About Arcutis Biotherapeutics, Inc.

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $784M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

More about ARQT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tejara Capital LTD, based on Form 13F filings with the SEC.

News

Stay updated on Tejara Capital LTD with notifications on news.

Account

Tejara Capital LTD Arcutis Biotherapeutics, Inc. Transaction History